Rebalance | 87155-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Rebalance
• 英文别名: 4-amino-N-pyrimidin-2-ylbenzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
• CAS: 87155-33-7
• 化学式: C22H23ClN8O2S
• 分子量: 499.0
• InChiKey: XIRVBAPVROALIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.38
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  184
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
  申请人：Baylor College Of Medicine

  公开号：EP2465510A2

  公开（公告）日：2012-06-20

  Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing pattern recognition receptor activity, and CD40 activity. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing CD40 activity without prostaglandin E2. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible chimeric molecule comprising a region of a pattern recognition receptor or an adaptor thereof.

  提供了通过诱导模式识别受体活性和 CD40 活性来激活抗原递呈细胞和激发免疫反应的方法。还提供了在不使用前列腺素 E2 的情况下通过诱导 CD40 活性来激活抗原递呈细胞和激发免疫反应的方法。还提供了通过诱导包含模式识别受体或其适配体区域的可诱导嵌合分子来激活抗原递呈细胞和激发免疫反应的方法。
• Induced activation in dendritic cells
  申请人：Slawin, Kevin M.

  公开号：EP2557164A1

  公开（公告）日：2013-02-13

  The present invention is directed to a composition and method which treat diseases and enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a costimulatory polypeptide.

  本发明涉及一种治疗疾病和增强调节性免疫反应的组合物和方法。更具体地说，本发明涉及基于树突状细胞的组合物，这些树突状细胞经过修饰，可表达一种诱导形式的成本刺激多肽。
• Compositions and methods for self-adjuvanting vaccines against microbes and tumors
  申请人：Kornbluth Richard Syd

  公开号：US10238734B2

  公开（公告）日：2019-03-26

  The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracelluar signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.

  本发明涉及增强免疫反应以预防或治疗感染或过度增殖性疾病（如癌症）的组合物和方法。更具体地说，本发明的组合物是一种免疫刺激性细胞内信号肽，它直接或间接地与一种能导致多聚化成三个或更多单元复合物的肽融合，其中细胞内信号肽必须存在于三个或更多单元的复合物中，才能刺激免疫反应。据预测，将这种融合构建体植入 HIV-1 等病毒中，或将其引入树突状细胞或肿瘤细胞中，将对人类、非人类哺乳动物、鸟类和鱼类产生积极的治疗效果。
• T cell receptors directed against Bob1 and uses thereof
  申请人：LEIDEN UNIVERSITY MEDICAL CENTER

  公开号：US10189880B2

  公开（公告）日：2019-01-29

  The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.

  该技术部分涉及诱导针对 Bob1 抗原的免疫应答的组合物和方法。本发明提供了通过诱导针对Bob1抗原的免疫应答来治疗过度增殖性疾病的方法；免疫应答可通过使用Bob1多肽片段诱导，或通过使用针对Bob1的T细胞受体特异性靶向Bob1表达细胞诱导。
• Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
  申请人：BELLICUM PHARMACEUTICALS, INC.

  公开号：US10888608B2

  公开（公告）日：2021-01-12

  The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.

  该技术总体上涉及免疫学领域，部分涉及激活 T 细胞和其他细胞的方法，从而产生针对目标抗原的免疫反应。该技术还涉及利用嵌合 MyD88 和 CD40 衍生多肽对表达嵌合抗原受体的治疗细胞进行成本刺激，嵌合抗原受体可识别靶抗原。该技术还部分涉及表达嵌合抗原受体的治疗细胞，其中嵌合抗原受体具有包括MyD88-和CD40衍生多肽的内域，以及使用改良治疗细胞治疗患者的方法。